1. Sun CC, Shargel L, Yu ABC. Biopharmaceutical aspects of the active pharmaceutical ingredient and pharmaceutical equivalence. In: Shargel L, Yu ABC, editors. Applied biopharmaceutics & pharmacokinetics. New York: McGraw-Hill Education; 2016. p. 529–43.
2. Censi R, Di Martino P. Polymorph impact on the bioavailability and stability of poorly soluble drugs. Molecules. 2015;20:18759–76. https://doi.org/10.3390/molecules201018759.
3. Suarez S, Marroum PJ, Hughes M. Biopharmaceutic considerations in drug product design and in vitro drug product performance. In: Shargel L, Yu ABC, editors. Applied biopharmaceutics & pharmacokinetics. New York: McGraw-Hill Education; 2016. p. 415–67.
4. Eddington ND, Ashraf M, Augsburger LL, Leslie JL, Fossler MJ, Lesko LJ, et al. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. Pharm Dev Technol. 1998;3:535–47. https://doi.org/10.3109/10837459809028636.
5. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Guidance for Industry. 2017. https://www.fda.gov/media/70963/download. Accessed 2 Mar 2021.